Correlation Of HSP90?,ALK And EGFR Gene Mutations In Non-Small Cell Lung Cancer

Research Background A large number of studies have shown that the high incidence and mortality of lung cancer has seriously endangered public health.Smoking and environmental pollution are the major causes for the greatly increased incidence of lung cancer.Surgery can be selected for the treatment of early lung cancer to improve the survival expectation of patients.With the development of tumor genetics in recent years,adenocarcinoma targeted drugs have been more and more widely used for the treatment of advanced patients.Because of the high mortality of lung cancer,early diagnosis of lung cancer has become a top priority.The diagnostic methods for lung cancer include imaging examination,serological examination,and tissue biopsy.The imaging manifestations of lung cancer are diverse,and there are many interfered factors that are easy to lead to missed diagnosis or misdiagnose.This is also the difficulty of early lung cancer screening.Tissue biopsy has great limitations due to its invasiveness and low positive detection rate.Relying on its convenience and speed and its irreplaceable role in early diagnosis,prognosis follow-up,recurrence monitoring and other aspects of tumors,the screening of serological indicators has become an important detection method for clinical screening of lung cancer.Heat shock protein 90 ? has received extensive attention in many studies on tumor markers.In the current era of personalized medical care,the identification of genetic changes is of great importance for targeted therapy.Mutations in EGFR genes and rearrangements of ALK genes also play an important role in the study of non-small cell lung cancer(NSCLC).However,it is unclear whether the expression of HSP90 in patients with NSCLC is related to the polymorphism of EGFR and AKL genes in the progression of the disease.Therefore,the potential value of HSP90 expression in early screening,clinical diagnosis andtreatment of NSCLC was preliminarily explored by detecting the level of HSP90 expression in patients with NSCLC and the mutation level of EGFR and AKL genes and identifying their correlation.Objective To explore the correlation between the expression level of serum HSP90? and the mutation levels of EGFR and AKL genes in patients with NSCLC.Method The serum and lung cancer tissue waxes of 89 patients being newly diagnosed as lung cancer through pathological diagnosis were collected.The concentrations of HSP90,CEA,NSE and cyfra21-1 biomarkers in serum of all lung cancer patients were detected using the ELISA method.Then the lung cancer patients were grouped with the maximum normal reference values of various biomarkers(the normal reference values of various biomarkers: HSP90 ?: 0 ~ 82.060ng/ml,CEA: 0 ~ 5ng/ml,NSE: 0 ~17.0ng/ml,CYFRA21-1 :0 ~ 3.3ng/ml).The mutation levels of EGFR and AKL genes in lung cancer tissues of the above patients were detected and analyzed by the gene company.The relationship between various clinical features and expression of HSP90?of lung cancer patients and the mutation levels of EGFR and AKL genes was analyzed using the statistical method.Results1.Basic features of patients A total of 89 cases were collected in this study,with an average age of 64.00±10.78 years.Among them,there were 53 males and 36 females.2.The mutation status of ALK and EGFR gene was not significantly correlated with the age,sex,metastasis,presence or absence of sputum,pathological classification and clinical stage of lung cancer.3.In lung cancer patients,comparing ALK and EGFR gene mutation positive groups with those negative groups,there is no significant difference in expression level of HSP90?? CEA?CYFR21-1andNSE.4.The positive rate of abnormal expression of CEA in serum of patients with EGFR mutation was significantly higher than that of patients without mutation.The difference was statistically significan(P=0.048)t.The positive rate of serum HSP90?,CEA,CYFR21-1 and NSE in NSCLC patients and the mutation of ALK gene were not No significant correlation.5.The serum HSP90? concentration in patients with metastatic NSCLC was significantly higher than that in patients without metastasis(P=0.027).The concentration of HSP90? and the age,sex,effusion of patients with NSCLC,pathological classification and clinical stage of lung cancer have no significant correlation.6.There was no significant correlation between serum HSP90? and CEA,CYFR21-1,and NSE expression rates in NSCLC patients.Conclusion: The expression of HSP90? in NSCLC patients is not related to the positive mutation of ALK and EGFR genes.